Research on the relations between the variation of miRNA-184 before and after treatment of acute myocardial infarction and prognosis

Z.-H. Liu, X.-P. Sun, S.-L. Zhou, H.-X. Wang

Department of Emergency, The affiliated Yidu Central Hospital of Weifang Medical College, Weifang, Shandong Province, China. wang_huaixin1@163.com

---

• Cardiology

OBJECTIVE: Several miRNAs have been shown to be released into the circulation and play roles during acute myocardial infarction (AMI). This study aimed at detecting the variation of miRNA-184 before and after treatment of acute myocardial infarction and assessing its prognostic value.

PATIENTS AND METHODS: 72 AMI patients participated in the study, alongside 10 patients with stable coronary disease and 10 healthy volunteers for comparison. The expression levels of miRNA-184 were measured in AMI patients at 6 h, 12 h, 48 h, 7 d, and 14 d after the onset of symptoms, using blood samples and an RT-PCR method. The levels were compared to single-time levels in the other two groups of individuals. The correlations between the N-terminal pro-brain natriuretic peptide (NT-proBNP) and parameters of the ventricular function (LVEDd and LVEF) and miRNA-184 levels were analyzed taking samples during a one-month follow-up visit. Finally, the correlation between the occurrence rate of major adverse cardiac effects (MACE) and miRNA-184 levels was analyzed evaluating the occurrence of MACE at a one-year follow-up visit.

RESULTS: The expression levels of miRNA-184 (6h) were significantly higher than those of the other two groups (p < 0.05). The levels reached a peak 24 h after the onset of symptoms and fell back to normal after 7 to 14 days (at which point the levels were no different than the levels in the other two groups). NT-proBNP and left ventricular end-diastolic diameter (LVEDd) were significantly lower after treatment, whereas the left ventricular ejection fraction (LVEF) increased significantly (p < 0.05). After a relevant Pearson analysis the expression level of miRNA-184 mRNA was positively correlated with ∆NT-proBNP (before and after treatment) (p < 0.05), with ∆LVEDd (before and after treatment) and with ∆LVEF (before and after treatment) (p < 0.05). Finally, 22 cases (36%) of major adverse cardiac events, MACE, were found in AMI patients, and the expression levels of miRNA-184 of the MACE group were significantly higher than those of the non-MACE group at each time point (p < 0.05).

CONCLUSIONS: miRNA-184 shows a dynamic evolution before and after percutaneous coronary intervention (PCI) treatment of AMI, and it is closely correlated with recent ventricular remodeling indexes and a future occurrence rate of MACE.

Free PDF Download